Navigation Links
TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
Date:11/25/2008

LA JOLLA, Calif., Nov. 25 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has purchased from Eli Lilly & Company a reduction in certain royalty amounts that may become payable to Eli Lilly on net sales of TorreyPines' clinical-stage compounds NGX426 and tezampanel, should either or both gain regulatory approval. Specifically, the top tier royalty rate will be reduced three percentage points and the middle tier royalty rate will be reduced one half percentage point. The bottom tier royalty rate will remain unchanged. In addition, certain milestone payments due to Eli Lilly related to the clinical development of NGX426 will be delayed from what was originally agreed. In exchange for the royalty rate reduction and change in milestone payment timing, TorreyPines issued to Eli Lilly two hundred thousand shares of TorreyPines Common Stock at fair market value. TorreyPines originally licensed NGX426 and tezampanel from Eli Lilly in April 2003.

"This agreement with Eli Lilly is another important part of our 2008 strategic plan to strengthen the company and build stockholder value," said Ev Graham, Chief Executive Officer of TorreyPines. "We believe the royalty rate reduction and delay in certain clinical milestone payments for NGX426 will further enhance the commercial value of NGX426 and tezampanel."

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognit
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
2. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
3. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
4. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
5. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
6. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
7. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
8. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
9. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
10. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
11. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2014)... nuclear fuel gets recycled, the process releases radioactive krypton ... basements with the related gas radon. A new porous ... appearing July 20 in Nature Materials shows ... but not out. , The CC3 material could ... from nuclear fuel or air in buildings and also ...
(Date:7/18/2014)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that ... operating results on Tuesday, August 5, 2014, before the ... conference call and simultaneous webcast at 8:30 AM Eastern ... access this call, dial (888) 660-6127 (U.S.) or (973) ... accessed from the ,Events and Presentations, page of Regeneron,s ...
(Date:7/18/2014)... is mostly neutral. That is, most of the ... number of electrons in the outer parts of atoms ... atoms. As one or more electrons are plucked ... much stronger positive pull from the nucleus. This ... ensures that those electrons are less vulnerable to the ...
(Date:7/18/2014)... 18, 2014 Global biotechnology company ... offices in Cambridge, MA, announces the launch of ... Software product that leverages the power of Next ... MiSeq sequencing platform. The assay and software have ... of Philadelphia (CHOP) and will include a new ...
Breaking Biology Technology:A noble gas cage 2A noble gas cage 3Highly charged ions 2Highly charged ions 3Highly charged ions 4Omixon Launches Holotype HLA for NGS-based HLA Genotyping 2Omixon Launches Holotype HLA for NGS-based HLA Genotyping 3
... large measure the ability to tune out negativity, author ... of southeastern Wisconsin technology professionals. , ,Kawasaki, managing partner ... "Art of the Start" and several other business books, ... of eInnovate. He poked some good-natured fun at politicians, ...
... may have an expo floor to rival any industry trade show, but ... a sale. , , The BIO Chicago show floor, the size ... globe. "I don't expect any of our end-user customers in the ... of Milwaukee-based Neurognostics said. "This is a probably a better ...
... A stem cell scientist from Harvard University dropped by Wisconsin's ... a hint of admiration, that it was abuzz with activity. ... Wisconsin exhibit than anywhere else I've been on the (exhibit) ... foot traffic at a trade show even one of ...
Cached Biology Technology:Beating back the bozos is an innovation must, says Kawasaki 2As BIO shows mass of competition, hunt for partners is on 2As BIO shows mass of competition, hunt for partners is on 3In competitive biotech world, Wisconsin can't afford to fall behind 2In competitive biotech world, Wisconsin can't afford to fall behind 3
(Date:7/21/2014)... and Dr. Mary Lou Applewhite Distinguished Professor in Department ... to an article in the scientific journal Nature ... into Primate Biology and Evolution," published on July 20. ... mobile elements that move by a sort of "copy ... important because it is the first "New World" monkey ...
(Date:7/21/2014)... La. Dr. Mark DeCoster, the James E. ... Louisiana Tech University, will present as an invited ... at the Biopolis Research and Development Center in ... faculty member in Louisiana Tech,s Institute for Micromanufacturing, ... 2D and 3D cell and tissue models." ...
(Date:7/21/2014)... see an innovation and think, "Of course! Why didn,t ... thoughts of our own invention, sparking ideas and building ... the International Space Station Program Science Office,s new 15-book ... have going on in orbit, their mental wheels may ... encourage investigators to propose new research and potentially make ...
Breaking Biology News(10 mins):LSU's Mark Batzer contributes to Nature Genetics article on marmoset genome 2Louisiana Tech University professor presents at International Bioprinting Congress 2International Space Station researcher guides aim to maximize science 2International Space Station researcher guides aim to maximize science 3International Space Station researcher guides aim to maximize science 4
... at the Southwest Foundation for Biomedical Research (SFBR) in ... levels of bad cholesterol to accumulate in the blood ... studied a strain of laboratory opossums developed at SFBR ... (LDL) cholesterol when fed a standard low-cholesterol diet, but ...
... 14, 2010: 5:00 p.m. U.S. Eastern Time) A new ... groups reveals an ominous finding: most of the world,s ... tradeare now clustered in just six percent of their ... scattered across Asia that are now the last hope ...
... published in the Sept. 15 edition of the Journal ... Edward H. Shortliffe, MD, PhD, points out that although ... role that information management and access play in healthcare ... informatics competency being developed in America,s future corps of ...
Cached Biology News:Scientists find gene for high cholesterol in blood 2Last strongholds for tigers identified in new study 2Last strongholds for tigers identified in new study 3Informatics = essential MD competency 2
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Macrophage-stimulating protein receptor...
Biology Products: